Neurology

Researchers identified macrophage-driven dural lymphatic refinement as a potential regulator of social behavior in ASD models.

A review of 6 novel drugs approved by the FDA, with links to coverage from Contemporary Pediatrics and other MJH Life Sciences brands.

A study found an initial decline in neurodevelopmental diagnoses during COVID-19 followed by a sustained postpandemic increase.

Identifying specific cognitive-linguistic deficits in kindergarten can predict early- and late-emerging dyslexia.

A review of 6 drugs approved by the FDA in Q1 2026, with links to coverage from Contemporary Pediatrics.

This new once-weekly intravenous therapy aims to treat the neurologic manifestations of Hunter syndrome in young children.

The approval marks the first treatment option for patients with this rare condition.

A study found no significant difference in increased intracranial pressure risk between surgical and conservative management for children with metopic synostosis.

A study found that 30 mg/kg/d methylprednisolone combined with tocilizumab was linked to improved neurological outcomes for encephalopathy.

FDA expands pitolisant indication to include cataplexy in patients 6 years and older with narcolepsy.

Phase 3 data show that high-dose I-ACQUIRE improved arm function at 6 months in infants and toddlers after perinatal stroke.

New phase 3 trial data reveal fremanezumab's effectiveness and safety for preventing migraines in children, offering a vital treatment option.

The phase 3 SPACE trial showed fremanezumab reduced monthly migraine days vs placebo in pediatric patients with episodic migraine.

A pediatric First Seizure Clinic model reduced time to specialist evaluation to days, enabling earlier diagnosis, testing, and treatment decisions.

The FDA approved Daybue Stix, a powder formulation of trofinetide, for Rett syndrome in patients 2 years or older.

FDA approves Itvisma for patients 2 years and older with SMA, making it the first FDA-approved gene replacement therapy for this population.

The clearnace was granted to the Ceribell System for electrographic seizure detection in newborns pre-term and older.

FDA adds boxed warning to Elevidys and limits use to ambulatory DMD patients ≥4 years after reports of fatal acute liver failure in non-ambulatory patients.

New research shows an increase in neurodevelopmental disorder risk among children exposed to maternal COVID-19 infection in utero.

The BeeLine trial is a placebo-controlled study designed to evaluate radiprodil’s impact on both seizure frequency and non-seizure symptoms associated with GRIN-NDD.

The FDA announces significant updates on acetaminophen risks in pregnancy and approves leucovorin calcium for treating CFD in children.

Zilganersen met the primary endpoint of gait stabilization, showing statistically significant benefit on gait speed and favorable safety.

According to new, real-world data for trofinetide, caregivers reported quality-of-life, alertness, and interaction improvements at 12 months of treatment.

Ji-Hyun Lee reports that short surgical exposure to sevoflurane did not affect IQ, behavior, or language outcomes in infants and toddlers.